PCM
MTEM

Prelude Capital Management’s Molecular Templates, Inc. MTEM Stock Holding History

Prelude Capital Management’s Portfolio MTEM Stock Details MTEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-53
Closed -$9K – 2160
2020
Q3 		$9K Buy
+53
New +$9.42K ﹤0.01% 1478
2018
Q2 		– Sell
-40
Closed -$5K – 2022
2018
Q1 		$5K Buy
+40
New +$6.02K ﹤0.01% 1421
2017
Q4 		– Sell
-60
Closed -$6K – 1807
2017
Q3 		$6K Buy
+60
New +$5.18K ﹤0.01% 1494
2017
Q2 		– Sell
-338
Closed -$32K – 1925
2017
Q1 		$32K Buy
338
+66
+24% +$6.18K ﹤0.01% 1172
2016
Q4 		$20K Buy
272
+171
+169% +$13.1K ﹤0.01% 1312
2016
Q3 		$11K Buy
101
+89
+742% +$12.2K ﹤0.01% 1423
2016
Q2 		$1K Buy
+12
New +$859 ﹤0.01% 1536
2014
Q3 		– Sell
-58
Closed -$38K – 2204
2014
Q2 		$38K Buy
+58
New +$38.4K 0.01% 1519

Other funds holding MTEM

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Prelude Capital Management's MTEM Position: Q4 2020 in Review

Prelude Capital Management sold out of Molecular Templates, Inc. (MTEM) in Q4 2020, closing a stake of 53 shares — an estimated $9K sold.

Prelude Capital Management first reported a position in MTEM in Q2 2014 and held it in 8 quarters. The position peaked at $38K in Q2 2014. 97 funds tracked by Wall St. Rank hold MTEM as of Q4 2020.

  • Prelude Capital Management reported no remaining Molecular Templates, Inc. position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 53 Molecular Templates, Inc. shares in Q4 2020, an estimated $9K.
  • Prelude Capital Management first reported a position in Molecular Templates, Inc. in Q2 2014 and held it in 8 quarters.
  • Prelude Capital Management's Molecular Templates, Inc. position peaked at $38K in Q2 2014.
  • 97 funds tracked by Wall St. Rank held Molecular Templates, Inc. as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.